BRANFORD, Conn., February 18, 2025--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26th.
Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™) will feature groundbreaking research through one company-led poster and two customer-led posters highlighting the transformative capabilities of NGPS in multi-omics research and drug discovery.
Scientific Posters Highlighting NGPS Innovation
Beyond the genome: Advancing our understanding of the proteome with Next-Generation Protein Sequencing™
Integrating long-read RNAseq and Next-Generation Protein Sequencing™ to explore proteoform variability
Identifying Protein Binding Partners at the Bench Using Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218012265/en/
Contacts
Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。